Latest on Pharmaceutical Companies: Special Research on PDL BioPharma,Pluristem, Proteon, QIAGEN, and Repligen

NEW YORK, February 18, 2015 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.  

Moments ago, Analysts Review released new research updates concerning several important developing situations including PDL BioPharma (NASDAQ: PDLI), Pluristem (NASDAQ: PSTI), Proteon (NASDAQ: PRTO), QIAGEN (NASDAQ: QGEN), and Repligen (NASDAQ: RGEN). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.

To access our full PDF reports on a complementary basis, please visit the links below.

--

Today's update concerns the following companies:

============

Full PDF Download Links (you may have to copy and paste the following links into your browser):

PDLI Research Report: ( http://get.analystsreview.com/pdf/?c=PDL%20BioPharma&d=18-Feb-2015&s=PDLI ),

PSTI Research Report: ( http://get.analystsreview.com/pdf/?c=Pluristem&d=18-Feb-2015&s=PSTI ),

PRTO Research Report: ( http://get.analystsreview.com/pdf/?c=Proteon&d=18-Feb-2015&s=PRTO ),

QGEN Research Report: ( http://get.analystsreview.com/pdf/?c=QIAGEN&d=18-Feb-2015&s=QGEN ),

RGEN Research Report: ( http://get.analystsreview.com/pdf/?c=Repligen&d=18-Feb-2015&s=RGEN ).

============

--

Analyst Update: Participations in Upcoming Conferences, Positive Findings from Clinical Trials, and Facility Expansions

Reviewed by: Rohit Tuli, CFA®  

The US market ended Tuesday's session with modest gains on growing optimism among investors that Greece will seek an extension to its rescue deal on Wednesday, following an unsuccessful talk on Monday. Although three US key benchmark indices started the day in the negative zone, stocks gained momentum in the afternoon hours as investors kept an eye on talks between Greece and its Eurozone creditors, helping S&P 500 and Dow Jones Industrial Average to score fresh records at day end. The S&P 500 gained 3.35 points or 0.16% to end at 2,100.34, another new record closing high. The Dow edged up 28.26 points or 0.16% to 18,047.58, which is a new 2015 record, while the NASDAQ Composite inched up 5.43 points or 0.11% to 4,899.27. During the day, US traders also largely shrugged off report from the National Association of Home Builders that showed an unexpected deterioration in homebuilder confidence. Meanwhile, the European market ended on mixed note on Tuesday on reports of Greece's resistance towards an extension of the current bailout program, while Eurozone ministers refused to loosen their terms.

PDL BioPharma, Inc. (PDL BioPharma) is scheduled to participate in two upcoming conferences. President and CEO John P. McLaughlin, will present at 2015 RBC Capital Markets' Global Healthcare Conference in New York, New York on February 25, 2015, at 9:30 a.m. EST; and at Cowen and Company 35th Annual Health Care Conference in Boston, Massachusetts on Wednesday, March 4, 2015, at 8:40 a.m. EST.

Pluristem Therapeutics, Inc. (Pluristem) has announced an important new finding and excellent safety profile from its Phase I/II clinical trial of PLacental eXpanded (PLX-PAD) cells in the treatment of muscle injury after total hip arthroplasty (THA). Data showed that six months after surgery the magnitude of improvement in muscle force of the contralateral (non-operated) gluteal muscle was approximately 40 times larger in patients treated with 150 million PLX-PAD cells than in those who received placebo.

Journal of Cardiovascular Pharmacology's published Positive Nonclinical Results of Proteon Therapeutics' (Proteon) PRT-201 (vonapanitase) in Peripheral Artery Disease (PAD) in its December 2014 issue. The ex vivo study evaluated the effect of a single treatment of PRT-201, an investigational drug, on atherosclerotic human arteries. The Company mentioned that the positive results support its clinical development program in PAD.

China's first population-based study of latent TB infection, published in The Lancet, showed that reliance on the 100-year-old tuberculin skin test has significantly overestimated latent tuberculosis infections in China, while results in the same patients using QIAGEN N.V's QuantiFERON-TB Gold (QFT®) provided a far better understanding of disease burden.

Repligen Corporation (Repligen) has completed an 11,000 square foot expansion of its U.S. manufacturing facility. The expansion includes a dedicated space for the production and assembly of Repligen's Alternating Tangential Flow System ("the ATF System"), the most recent addition to the Company's upstream bioprocessing product portfolio. The ATF System is a market-leading product line used to significantly increase cell density and product yield during the fermentation step of the biologic drug manufacturing process.

--

About Analysts Review  

At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.

--

Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.

Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review